The latest price trends and influencing factors of Osimertinib/Tagressa in 2025

Osimertinib (Osimertinib), trade name Tagrisso, is a targeted therapy drug for non-small cell lung cancer (NSCLC). It is mainly used to treat patients with advanced or metastatic lung cancer who are positive for EGFR gene mutations. With the continuous development of cancer treatment drugs around the world, osimertinib has gradually become an important drug in this field due to its remarkable efficacy, especially in the treatment of EGFR T790M mutation-positive lung cancer. For many patients, the price of the drug is an important factor related to treatment accessibility. The price of osimertinib in 2025 has become the focus of attention of patients and the medical industry.

The price of osimertinib is affected by many factors, including production costs, market demand, medical insurance policies and international patents. Since its launch, the price of osimertinib has undergone several adjustments. Osimertinib, as an important targeted anti-cancer drug, has been officially launched in the Chinese market. Currently, common specifications include80mg*30 tablets and 40mg*30 tablets, with each box selling for approximately RMB 4,000 to RMB 6,000. In addition, osimertinib has been included in the medical insurance system, and patients can relieve some of their financial pressure through reimbursement policies.

For patients, when choosing osimertinib treatment, in addition to considering the efficacy of the drug, the price factor is also very important. In comparison, the original drug price of osimertinib in overseas markets is more expensive, and usually the price of each box sold may exceed US$10,000. In the international market, many countries have also launched generic drugs of osimertinib. For example, factories in Laos and Bangladesh produce 80mg*30 tablets, which are priced at more than 800 yuan (the specific price will vary due to exchange rate fluctuations), which is relatively more affordable.

Reference materials:https://go.drugbank.com/drugs/DB09330